239 related articles for article (PubMed ID: 19039757)
21. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Boden WE; Hoekstra J; Miller CD
Am J Emerg Med; 2008 Feb; 26(2):212-20. PubMed ID: 18272105
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
23. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.
Smit JJ; van Werkum JW; ten Berg J; Slingerland R; Ottervanger JP; Heestermans T; Dill T; Hamm C; van 't Hof AW;
Heart; 2010 Nov; 96(22):1815-20. PubMed ID: 20889993
[TBL] [Abstract][Full Text] [Related]
24. Effects of abciximab as adjunctive therapy in primary percutaneous coronary intervention patients (results from the DANAMI-2 trial).
Sejersten M; Maynard C; Clemmensen P;
Acute Card Care; 2006; 8(2):75-82. PubMed ID: 16885070
[TBL] [Abstract][Full Text] [Related]
25. Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction.
Funck-Jensen KL; Dalsgaard J; Grove EL; Hvas AM; Kristensen SD
Platelets; 2013; 24(7):528-37. PubMed ID: 23216571
[TBL] [Abstract][Full Text] [Related]
26. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
27. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
28. Aspiration thrombectomy during primary percutaneous coronary intervention as adjunctive therapy to early (in-ambulance) abciximab administration in patients with acute ST elevation myocardial infarction: an analysis from Leiden MISSION! acute myocardial infarction treatment optimization program.
Ahmed TA; Atary JZ; Wolterbeek R; Hasan-Ali H; Abdel-Kader SS; Schalij MJ; Jukema JW
J Interv Cardiol; 2012 Feb; 25(1):1-9. PubMed ID: 22059390
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shimada YJ; Nakra NC; Fox JT; Kanei Y
Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
[TBL] [Abstract][Full Text] [Related]
30. Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment.
Becatti M; Fiorillo C; Gori AM; Marcucci R; Paniccia R; Giusti B; Violi F; Pignatelli P; Gensini GF; Abbate R
Atherosclerosis; 2013 Dec; 231(2):392-400. PubMed ID: 24267257
[TBL] [Abstract][Full Text] [Related]
31. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
32. A study of platelet aggregation in patients with acute myocardial infarction at presentation and after 48 hrs of initiating standard anti platelet therapy.
Guha S; Mookerjee S; Lahiri P; Mani S; Saha J; Guha S; Majumdar D; Mandal MM; Bhattacharya R
Indian Heart J; 2011; 63(5):409-13. PubMed ID: 23550417
[TBL] [Abstract][Full Text] [Related]
33. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
34. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction.
Kubica A; Kasprzak M; Siller-Matula J; Koziński M; Pio Navarese E; Obońska K; Andruszkiewicz A; Sztuba B; Fabiszak T; Swiątkiewicz I; Paciorek P; Kubica J
Eur J Pharmacol; 2014 Nov; 742():47-54. PubMed ID: 25199965
[TBL] [Abstract][Full Text] [Related]
35. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial.
Desch S; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Pauschinger M; Kerber S; Kleinertz K; de Waha S; Eitel I; Schuler G; Thiele H
J Am Coll Cardiol; 2013 Sep; 62(13):1214-5. PubMed ID: 23850911
[No Abstract] [Full Text] [Related]
36. Switching from generic to brand clopidogrel in male patients after ST-elevated myocardial infarction.
Syvolap VV; Franskavichene LV; Golukhova EZ; Serebruany VL
Cardiology; 2014; 129(2):103-5. PubMed ID: 25227134
[TBL] [Abstract][Full Text] [Related]
37. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
Kubica A; Kasprzak M; Obońska K; Fabiszak T; Laskowska E; Navarese EP; Koziński M; Sztuba B; Świątkiewicz I; Grześk G; Kubica J
Pharmacology; 2015; 95(1-2):50-8. PubMed ID: 25592409
[TBL] [Abstract][Full Text] [Related]
38. Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide?
Kleiman NS
Nat Clin Pract Cardiovasc Med; 2005 Jul; 2(7):344-5. PubMed ID: 16265559
[No Abstract] [Full Text] [Related]
39. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.
Jeong YH; Cho JH; Kang MK; Koh JS; Kim IS; Park Y; Hwang SJ; Kwak CH; Hwang JY
Thromb Res; 2010 Oct; 126(4):e334-8. PubMed ID: 20451242
[TBL] [Abstract][Full Text] [Related]
40. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Koziński M; Grześk G; Kubica J
Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
